+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID06606821

Study of Tirzepatide Effects on Coronary Plaque and Heart Microvascular Function in Overweight and Obese Adults with Coronary Artery Disease

Led by Tina Vilsbøll · Updated on 2025-05-22

124

Participants Needed

3

Research Sites

71 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term effects of tirzepatide, given once weekly, compared to placebo on coronary plaque composition, plaque burden, and microvascular function in overweight and obese adults with stable coronary artery disease CAD. This Phase 4 proof-of-principle study aims to explore how tirzepatide may reduce coronary lipid accumulation and the progression of atheromatosis in individuals with high-risk atherosclerosis. The study also includes a baseline sub-study to identify metabolic and cardiovascular predictors of high arteriosclerotic plaque burden and to build a cohort for future research. Participants will be randomly assigned to receive either tirzepatide or placebo as a once-weekly subcutaneous injection for 52 weeks. Tirzepatide is an investigational drug studied for its anti-atherogenic effects, while placebo injections match in volume and excipients but contain no active drug. The study uses advanced imaging techniques including near-infrared spectroscopy NIRS and intravascular ultrasound IVUS to assess changes in plaque lipid content and burden. Microvascular function will be evaluated using coronary flow reserve measurements. Throughout the 52-week treatment period, participants will undergo detailed assessments including imaging to measure lipid core burden index and percent atheroma volume. Researchers will monitor coronary flow reserve and the number of high-risk coronary lesions to evaluate treatment effects. Safety monitoring and follow-up will continue throughout the study duration, with data collected to understand tirzepatides impact on coronary plaque and microvascular function in this population.

CONDITIONS

Brief Title

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Research Team

D

Daniel Raaschou-Oddershede, MD

C

Christine Rode Schwarz, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here